Neoclone

NeoClone was a biotechnology company based in Madison, Wisconsin, that specialized in the discovery and development of custom monoclonal antibodies. The company utilized its proprietary NeoAb platform, a retroviral-based technology designed to generate high-affinity antibodies more efficiently than traditional hybridoma methods. NeoClone provided services to the research, diagnostic, and therapeutic sectors of the life sciences industry. In 2011, the company's catalog of over 800 antibodies and related assets was acquired by Abcam, a global leader in research tools. Following the asset sale, the company's primary operations transitioned as its core technology and products were integrated into the acquirer's portfolio.